| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 57894-0510-01 | 57894-0510 | AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) | RYBREVANT FASPRO | 1600.0 mg/10mL, 20000.0 mg/10mL | Immunotherapy | Bispecific Antibody | EGFR, MET | Subcutaneous | Dec 17, 2025 | In Use | |
| 63459-0910-18 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Jan 7, 2015 | In Use | |
| 00004-0365-09 | 00004-0365 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Nov 1, 2011 | In Use | |
| 76282-0720-67 | 76282-0720 | LANREOTIDE ACETATE | LANREOTIDE ACETATE | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | May 30, 2025 | In Use | ||
| 00006-5083-01 | 00006-5083 | Pembrolizumab and berahyaluronidase alfa-pmph | KEYTRUDA QLEX | 2000.0 U/mL, 165.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Subcutaneous | Sep 19, 2025 | In Use | |
| 50242-0108-01 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 22, 2017 | In Use | |
| 75987-0111-11 | 75987-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | In Use | |
| 63459-0910-12 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
| 63459-0910-01 | 63459-0910 | tbo-filgrastim | Granix | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 11, 2013 | In Use | |
| 82497-0132-01 | 82497-0132 | Eflapegrastim-xnst | Rolvedon | 13.2 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Dec 11, 2025 | In Use | |
| 00069-0292-10 | 00069-0292 | filgrastim-aafi | Nivestym | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Sep 24, 2018 | In Use | |
| 50090-2027-00 | 50090-2027 | Goserelin acetate | Zoladex | 3.6 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Sep 23, 2015 | In Use | ||
| 42238-0111-12 | 42238-0111 | Interferon gamma-1b | Actimmune | 100.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Dec 1, 2013 | Jan 17, 2018 | No Longer Used |
| 72606-0059-01 | 72606-0059 | Denosumab-bmwo | Denosumab-BMWO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 10, 2025 | In Use | |
| 85043-0075-50 | 85043-0075 | Leuprolide acetate | Vabrinty | 7.5 mg/.25mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb 2, 2026 | In Use | ||
| 55513-0190-01 | 55513-0190 | Pegfilgrastim | Neulasta | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Apr 1, 2002 | In Use | |
| 55513-0730-21 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Apr 15, 2025 | In Use | |
| 50242-0245-01 | 50242-0245 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | Jun 29, 2020 | In Use | |
| 43598-0308-23 | 43598-0308 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Nov 6, 2023 | In Use | |
| 82737-0073-01 | 82737-0073 | Motixafortide | Aphexda | 62.0 mg/1.7mL | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Subcutaneous | Sep 8, 2023 | In Use | |
| 00004-0357-99 | 00004-0357 | Peginterferon alfa-2a | Pegasys | 180.0 ug/.5mL | Immunotherapy | Cytokine | Interferon | Subcutaneous | Aug 22, 2011 | Sep 19, 2014 | No Longer Used |
| 15054-0120-01 | 15054-0120 | Lanreotide acetate | Somatuline Depot | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Nov 14, 2007 | Aug 31, 2016 | No Longer Used | |
| 62756-0452-37 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Feb 24, 2025 | In Use | ||
| 00024-0222-05 | 00024-0222 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 23, 2002 | May 31, 2016 | No Longer Used | ||
| 69097-0870-67 | 69097-0870 | Lanreotide acetate | Lanreotide Acetate | 120.0 mg/.5mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | Dec 24, 2021 | In Use |
Found 12250 results — Export these results
Home